Roche to up R&D spend as it realigns operations
Roche announced plans to increase spending on research and development and introduced a new operating model reorganizing its development and marketing efforts.
Roche said its R&D spending would rise further than the $4.8 billion it spent in 2006 over the next few years but did not provide exact figures.
The drugmaker also announced plans to reorganize its business operations around five disease biology units combining discovery, R&D and marketing.
The cancer drugs unit will be housed in Nutley, NJ, Roche said. The virology and inflammation units will be located in Palo Alto, CA and metabolism and central nervous system will be housed at Roche facilities in Basel, Switzerland.
“By combing existing expertise in disease biology areas, we will further enhance the optimal conditions for bringing future innovations to fruition faster and more efficiently – with clear benefits for patients and doctors,” CEO Franz Humer said.